États-Unis · Agences & temps réel · PR Newswire

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

Publié par PR Newswire · États-Unis il y a 3 h

~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

À lire aussi

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

Partager

À lire aussi

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows